title: Loss of visual field among patients with birdshot chorioretinopathy.
abstract: OBJECTIVE
  To describe the prevalence and incidence of loss of visual field among patients with birdshot chorioretinopathy (BSCR) and to describe the effect of therapy on such field loss in these patients.
  
  
  METHODS
  Retrospective cohort study.
  
  
  METHODS
  
  
  
  METHODS
  Single-center, academic practice.
  
  
  METHODS
  Fifty-five patients with BSCR evaluated from January 1984 through July 2006.
  
  
  METHODS
  Demographic, clinical, and visual field data were collected retrospectively.
  
  
  METHODS
  Visual field loss is defined as an abnormal visual field score on Goldmann perimetry within six months of presentation and during follow-up; rate of visual field loss is defined as the number of degrees lost per year.
  
  
  RESULTS
  Forty-eight eyes of 24 patients had Goldmann visual fields performed within six months of presentation and of these eyes, 75% and 56% had abnormal field scores for the I-4 and IV-4 isopters, respectively. Of the 28 eyes of 14 patients that received immunosuppressive drug therapy during the follow-up period, the rate of visual field "loss" prior to treatment was 107 degrees/year (95% confidence interval [CI]: 65, 148 degrees/year) and 56 degrees/year (95% CI: 5, 109 degrees/year) for the I-4 and IV-4 isopters, respectively. The rate of "gain" after institution of immunosuppressive drug therapy was 53 degrees/year (95% CI: 10 degrees lost/year, 98 degrees gained/year) and 30 degrees/year (95% CI: 20 degrees lost/year, 81 degrees gained/year) for each isopter.
  
  
  CONCLUSIONS
  Visual field loss was common among our patients with BSCR. Usage of immunosuppressive drug therapy may reverse some of the visual field loss while therapy is employed.
authors.affiliation: Department of Ophthalmology, the Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. jthorne@jhmi.edu
authors.forename: Jennifer E
authors.initials: JE
authors.lastname: Thorne
authors.forename: Douglas A
authors.initials: DA
authors.lastname: Jabs
authors.forename: Sanjay R
authors.initials: SR
authors.lastname: Kedhar
authors.forename: George B
authors.initials: GB
authors.lastname: Peters
authors.forename: James P
authors.initials: JP
authors.lastname: Dunn
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D015862:Choroid Diseases / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015994:Incidence; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D012164:Retinal Diseases / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D012189:Retrospective Studies; D014786:Vision Disorders / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology*; D058609:Visual Field Tests; D014794:Visual Fields
chemical_list: D007166:Immunosuppressive Agents